AbbVie said the EMA's CHMP adopted a positive opinion recommending approval of MAVIRET for acute hepatitis C infection in adults and children aged 3 and older. The regulatory step is supportive for the drug's European expansion and could broaden the patient pool if finalized. The news is positive for AbbVie's hepatitis C franchise, though the immediate market impact is likely limited unless full approval follows.
AbbVie said the EMA's CHMP adopted a positive opinion recommending approval of MAVIRET for acute hepatitis C infection in adults and children aged 3 and older. The regulatory step is supportive for the drug's European expansion and could broaden the patient pool if finalized. The news is positive for AbbVie's hepatitis C franchise, though the immediate market impact is likely limited unless full approval follows.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
